Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Investigator-blinded, Active-controlled Phase 3 Study to Prove the Non-inferior Efficacy of a Clotrimazole Ovule (500 mg) Versus a Clotrimazole Vaginal Tablet (500 mg) in Vaginal Candidiasis

NCT00755053 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00755053
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00755053 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Investigator-blinded, Active-controlled Phase 3 Study to Prove the Non-inferior Efficacy of a Clotrimazole Ovule (500 mg) Versus a Clotrimazole Vaginal Tablet (500 mg) in Vaginal Candidiasis
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2008
Completion date
May 31, 2009
Enrollment
466 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

clotrimazole, ovulen, vulvovaginal candidiasis